NLS Pharmaceutics (NLSP) announced that it intends to effect a reverse share split of the company’s issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10. The company’s common shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, under the new trading symbol (NCEL), and new name, NewcelX, following the anticipated closing of the merger with Kadimastem.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics and Kadimastem Finalize Merger Conditions
- NLS Pharmaceutics Announces Strategic Collaboration for Gene-Edited Cell Therapies
- NLS Pharmaceutics partner Kadimastem to collaborate with TargetGene
- NLS Pharmaceutics and Kadimastem Secure Nasdaq Approval for Merger
- NLS Pharmaceutics receives Nasdaq approval for listing